To evaluate the therapeutic effect of oral alitretinoin (Toctino®) in the treatment of CLE with respect to proportion of responders based on the Revised Cutaneous Lupus Disease Area and Severity Index (RCLASI) activity score for skin lesions at baseline and after 24 weeks of treatment or at the latest assessment for patients who withdrew prematurely. Response is defined as a reduction of 50% in the total RCLASI compared to the baseline value ("RCLASI 50").
Full Title of Study: “Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Multicentre, Open-Label, Prospective Pilot Study”
- Study Type: Interventional
- Study Design
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: April 2014
- Drug: Alitretinoin
- 1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
Arms, Groups and Cohorts
- Experimental: Alitretinoin
Clinical Trial Outcome Measures
- Primary efficacy outcome is the response rate at week 24 or at the latest assessment for patients who withdrew prematurely.
- Time Frame: Week 24 or at the latest assessment for patients who withdrew prematurely.
- Response is defined as a reduction of 50% in the total RCLASI activity for skin lesions, compared to the baseline value (“RCLASI 50″)
- Proportion of patients with RCLASI 50 at week 12 of treatment.
- Time Frame: Week 12 of treatment
- Proportion of patients with at least partial response at end of therapy (with regard to RCLASI activity score for skin lesions).
- Time Frame: End of therapy (up to 24 weeks)
- Patient’s global assessment and VAS for itch and pain 12 weeks after the beginning of treatment.
- Time Frame: 12 weeks after the beginning of treatment
- Number of Participants with Adverse Events (AEs) and their severity.
- Time Frame: 24 weeks of treatment + 5 weeks of follow up
- Patient’s global assessment and VAS for itch and pain at the end of therapy.
- Time Frame: End of therapy (up to 24 weeks)
Participating in This Clinical Trial
- A clinical and histological diagnosis of CLE (DLE, SCLE, LET) who failed to respond to topical corticosteroids;
- Total RCLASI activity score of skin lesions >6 (at least 3 points in at least 2 locations);
- At least one primary but preferably 2 methods of contraception;
- Systemic Lupus Erythematosus (SLE) with major systemic organ involvement, e.g. clinical significant renal involvement, requiring systemic medical treatment for the disease;
- Clinically significant illness that may influence the outcome of the study in the four weeks before and during the study;
- Active severe infection diseases, including chronic or localized;
- Patients with hepatic insufficiency (AST, ALT > 2.5 x ULN), severe renal failure (creatinine clearance < 60ml/min), or hypercholesterolemia characterized by:
1. Fasting triglyceridemia > 1.5 x upper limit of normal (ULN)
2. Fasting total cholesterol > 1.5 x ULN
3. Fasting low-density lipoprotein (LDL) cholesterol > 1.5x ULN
- Patients with known hypersensitivity to other retinoids or vitamin A derivatives, or to any study medication component, especially soybean oil and partly hydrogenated soybean oil;
- Patients with cardiovascular risk factors that would exclude a starting dose of 30 mg of alitretinoin;
- Topical corticosteroids within 14 days prior to dosing;
- Patients treated with any systemic or topical retinoids within 4 weeks before start of study treatment;
- Drugs with a potential for drug-drug interaction, such as systemic tetracyclines, ketoconazole, or St. John‟s Wort within 1 week, or receiving systemic itraconazole within 2 weeks, before start of study treatment;
- Initiation or change in the dose of any current systemic medication for the treatment of CLE/SLE prior to the study (time depending on drug class and half-life);
- Treatment with immunosuppressive drugs for other reasons, 4 weeks prior and within the study;
- Concomitant medication with drugs with a known photosensitizing potential, e.g. tetracyclines, griseofulvin, thiazides, furosemide, sulfonamides or tolbutamide;
- Drugs associated to CLE-induction: terbinafine, hydrochlorothiazide, diltiazem, verapamil, nifedipine, nitrendipine, fluorouracil, penicillamine, infliximab, adalimumab, etanercept, pantoprazole;
Other protocol-defined inclusion/exclusion criteria may apply
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- University Hospital Muenster
- Basilea Pharmaceutica International Ltd
- Provider of Information About this Clinical Study
- Overall Official(s)
- Annegret Kuhn, Prof. Dr., Principal Investigator, Department of Dermatology, University Hospital Muenster, Muenster, Germany
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.